Amanote Research
Register
Sign In
Discover open access scientific publications
Search, annotate, share and cite publications
Publications by Frank C. Albers
Assessment of the Long-Term Safety of Mepolizumab and Durability of Clinical Response in Patients With Severe Eosinophilic Asthma
Journal of Allergy and Clinical Immunology
Allergy
Immunology
Mepolizumab Reduces Exacerbations in Patients With Severe Eosinophilic Asthma, Irrespective of Body Weight/Body Mass Index: Meta-Analysis of MENSA and MUSCA
Respiratory Research
Pulmonary
Respiratory Medicine
Related publications
Long-Term Efficacy and Safety of Mepolizumab in Patients With Severe Eosinophilic Asthma: A Multi-Center, Open-Label, Phase IIIb Study
Clinical Therapeutics
Pharmacology
Real-World Safety of Treatment With Mepolizumab and Reslizumab in Patients With Severe Eosinophilic Asthma
Journal of Allergy and Clinical Immunology
Allergy
Immunology
Patients With Severe Eosinophilic Asthma Treated With Mepolizumab: Results From Our Clinical Practice
Journal of Allergy and Clinical Immunology
Allergy
Immunology
Prs55 - Cost-Effectiveness of Mepolizumab in Severe Eosinophilic Asthma Patients in France
Value in Health
Medicine
Health Policy
Public Health
Occupational Health
Environmental
Efficacy and Safety of Treatment With Biologicals (Benralizumab, Dupilumab, Mepolizumab, Omalizumab and Reslizumab) for Severe Eosinophilic Asthma
Allergy: European Journal of Allergy and Clinical Immunology
Allergy
Immunology
Mepolizumab for Severe Refractory Eosinophilic Asthma: Evidence to Date and Clinical Potential
Therapeutic Advances in Chronic Disease
Medicine
Bronchial Thermoplasty: Long-Term Safety and Effectiveness in Patients With Severe Persistent Asthma
Journal of Allergy and Clinical Immunology
Allergy
Immunology
Prospective Open-Label Study of 48-Week Subcutaneous Administration of Mepolizumab in Japanese Patients With Severe Eosinophilic Asthma
Journal of Allergy and Clinical Immunology
Allergy
Immunology
Favorable Clinical Efficacy of Mepolizumab on the Upper and Lower Airways in Severe Eosinophilic Asthma: A 48-Week Pilot Study
European Annals of Allergy and Clinical Immunology
Allergy
Immunology
